Antiepileptic action of N-palmitoylethanolamine through CB1 and PPAR-α receptor activation in a genetic model of absence epilepsy

Neuropharmacology

Volumn 69, Issue , 2013, Pages 115-126

  Citraro, Rita ^a   Russo, Emilio ^a   Scicchitano, Francesca ^a   Van Rijn, Clementina M ^b   Cosco, Donato ^a   Avagliano, Carmen ^c   Russo, Roberto ^c   D'Agostino, Giuseppe ^c   Petrosino, Stefania ^d   Guida, Francesca ^e   Gatta, Luisa ^e   Van Luijtelaar, Gilles ^b   Maione, Sabatino ^e   Di Marzo, Vincenzo ^d   Calignano, Antonio ^c   De Sarro, Giovambattista ^a  

^a UNIVERSITY MAGNA GRAECIA OF CATANZARO   (Italy)

^b RADBOUD UNIVERSITY   (Netherlands)

^c UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^d CNR   (Italy)

^e SECOND UNIVERSITY OF NAPLES   (Italy)

Author keywords

Absence seizures; Anandamide; Endocannabinoids; GW6471; SR141716; SWDs

Indexed keywords

2 ARACHIDONOYLGLYCEROL; ANANDAMIDE; CANNABINOID 1 RECEPTOR; GW 6471; PALMIDROL; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ANTAGONIST; RIMONABANT; UNCLASSIFIED DRUG;

ABSENCE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTICONVULSANT ACTIVITY; ARTICLE; BRAIN CORTEX; BRAIN LEVEL; CONTROLLED STUDY; DRUG ANTAGONISM; ELECTROENCEPHALOGRAPHY; EPILEPTIC DISCHARGE; GENETIC MODEL; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; RECEPTOR UPREGULATION; SPIKE WAVE; THALAMUS;

ANIMALS; ANTICONVULSANTS; ARACHIDONIC ACIDS; CALCIUM CHANNEL BLOCKERS; CANNABINOID RECEPTOR ANTAGONISTS; DOSE-RESPONSE RELATIONSHIP, DRUG; ELECTROENCEPHALOGRAPHY; ENDOCANNABINOIDS; EPILEPSY, ABSENCE; ETHANOLAMINES; GLYCERIDES; INJECTIONS, INTRAVENTRICULAR; LIPID METABOLISM; MALE; OXAZOLES; PALMITIC ACIDS; PIPERIDINES; POLYUNSATURATED ALKAMIDES; PPAR ALPHA; PYRAZOLES; RATS; RATS, WISTAR; RECEPTOR, CANNABINOID, CB1; TYROSINE;

EID: 84875265975     PISSN: 00283908     EISSN: 18737064     Source Type: Journal    
DOI: 10.1016/j.neuropharm.2012.11.017     Document Type: Article

References (64)

1. S. Ben Shabat, E. Fride, T. Sheskin, T. Tamiri, M.H. Rhee, Z. Vogel, T. Bisogno, L. De Petrocellis, and V. Di Marzo An entourage effect: inactive endogenous fatty acid glycerol esters enhance 2-arachidonoylglicerol cannabinoid activity Eur. J. Pharmacol. 353 1998 23 31
2. T. Bisogno, S. Maurelli, D. Melck, L. De Petrocellis, and V. Di Marzo Biosynthesis, uptake, and degradation of anandamide and palmitoylethanolamide in leukocytes J. Biol. Chem. 272 1997 3315 3323
3. H. Cadas, E. di Tomaso, and D. Piomelli Occurrence and biosynthesis of endogenous cannabinoid precursor, N-arachidonoyl phosphatidylethanolamine, in rat brain J. Neurosci. 17 1997 1226 1242
4. A. Calignano, G. La Rana, A. Giuffrida, and D. Piomelli Control of pain initiation by endogenous cannabinoids Nature 394 1998 277 281
5. A. Calignano, G. La Rana, and D. Piomelli Antinociceptive activity of the endogenous fatty acid amide, palmitylethanolamide Eur. J. Pharmacol. 419 2001 191 198
6. A.M. Coenen, and E.L. Van Luijtelaar Genetic animal models for absence epilepsy: a review of the WAG/Rij strain of rats Behav. Genet. 33 2003 635 655
7. S. Conti, B. Costa, M. Colleoni, D. Parolaro, and G. Giagnoni Antiinflammatory action of endocannabinoid palmitoylethanolamide and the synthetic cannabinoid nabilone in a model of acute inflammation in the rat Br. J. Pharmacol. 135 2002 181 187
8. G. D'Agostino, G. La Rana, R. Russo, O. Sasso, A. Iacono, E. Esposito, G.M. Raso, S. Cuzzocrea, J. Lo Verme, D. Piomelli, R. Meli, and A. Calignano Acute intracerebroventricular administration of palmitoylethanolamide, an endogenous peroxisome proliferator-activated receptor-alpha agonist, modulates carrageenan-induced paw edema in mice J. Pharmacol. Exp. Ther. 322 2007 1137 1143
9. G. D'Agostino, G. La Rana, R. Russo, O. Sasso, A. Iacono, E. Esposito, G. Mattace Raso, S. Cuzzocrea, J. Lo verme, D. Piomelli, R. Meli, and A. Calignano Central administration of palmitoylethanolamide reduces hyperalgesia in mice via inhibition of NF-kappa B nuclear signalling in dorsal root ganglia Eur. J. Pharmacol. 613 2009 54 59
10. G. D'Agostino, R. Russo, C. Avagliano, C. Cristiano, R. Meli, and A. Calignano Palmitoylethanolamide protects against the amyloid-β25-35-induced learning and memory impairment in mice, an experimental model of Alzheimer disease Neuropsychopharmacology 37 2012 1784 1792
11. N.A. Darmani, A.A. Izzo, B. Degenhardt, M. Valenti, G. Scaglione, R. Capasso, I. Sorrentini, and V. Di Marzo Involvement of the cannabimimetic compound, N-palmitoyl-ethanolamine, in inflammatory and neuropathic conditions: review of the available pre-clinical data, and first human studies Neuropharmacology 48 2005 1154 1163
12. V. de Novellis, L. Luongo, F. Guida, L. Cristino, E. Palazzo, R. Russo, I. Marabese, G. D'Agostino, A. Calignano, F. Rossi, V. Di Marzo, and S. Maione Effects of intra-ventrolateral periaqueductal grey palmitoylethanolamide on thermoceptive threshold and rostral ventromedial medulla cell activity Eur. J. Pharmacol. 676 2012 41 50
13. L. De Petrocellis, J.B. Davis, and V. Di Marzo Palmitoylethanolamide enhances anandamide stimulation of human vanilloid VR1 receptors FEBS Lett. 506 2001 253 256
14. D. Deplanque, P. Gele, O. Petrault, I. Six, C. Furman, M. Bouly, S. Nion, B. Dupuis, D. Leys, J.C. Fruchart, R. Cecchelli, B. Staels, P. Duriez, and R. Bordet Peroxisome proliferator-activated receptor-a activation as a mechanism of preventive neuroprotection induced by chronic fenofibrate treatment J. Neurosci. 23 2003 6264 6271
15. W.A. Devane, A. Breuer, T. Sheskin, T.U. Järbe, M.S. Eisen, and R. Mechoulam A novel probe for the cannabinoid receptor J. Med. Chem. 35 1992 2065 2069
16. W.P. Farquhar-Smith, S.I. Jaggar, and A.S.C. Rice Attenuation of nerve growth factor-induced visceral hyperalgesia via cannabinoid CB1 and CB2-like receptors Pain 97 2002 11 21
17. A. Franklin, S. Parmentier-Batteur, L. Walter, D.A. Greenberg, and N. Stella Palmitoylethanolamide increases after focal cerebral ischemia and potentiates microglial cell motility J. Neurosci. 23 2003 7767 7775
18. J. Fu, S. Gaetani, F. Oveisi, J. Lo Verme, A. Serrano, F. Rodríguez De Fonseca, A. Rosengarth, H. Luecke, B. Di Giacomo, G. Tarzia, and D. Piomelli Oleylethanolamide regulates feeding and body weight through activation of the nuclear receptor PPAR-alpha Nature 425 2003 90 93
19. P. Gareri, D. Condorelli, N. Belluardo, R. Citraro, V. Barresi, A. Trovato-Salinaro, G. Mudò, G.F. Ibbadu, E. Russo, and G. De Sarro Antiabsence effects of carbenoxolone in two genetic animal models of absence epilepsy (WAG/Rij rats and lh/lh mice) Neuropharmacology 49 2005 551 563
20. P. Garg, R.S. Duncan, S. Kaja, and P. Koulen Intracellular mechanisms of N-acylethanolamine-mediated neuroprotection in a rat model of stroke Neuroscience 166 2010 252 262
21. G. Griffin, Q. Tao, and M.E. Abood Cloning and pharmacological characterization of the rat cb(2) cannabinoid receptor J. Pharmacol. Exp. Ther. 292 2000 886 894
22. R. Gülhan Aker, K. Tezcan, N. Carçak, E. Sakalli, D. Akin, and F.Y. Onat Localized cortical injections of ethosuximide suppress spike-and-wave activity and reduce the resistance to kindling in genetic absence epilepsy rats (GAERS) Epilepsy Res. 89 2010 7 16
23. A.A. Gurbanova, R.G. Aker, S. Sirvanci, T. Demiralp, and F.Y. Onat Intra-amygdaloid injection of kainic acid in rats with genetic absence epilepsy: the relationship of typical absence epilepsy and temporal lobe epilepsy J. Neurosci. 28 2008 7828 7836
24. H.S. Hansen, L. Lauritzen, B. Moesgaard, A.M. Strand, and H.H. Hansen Formation of N-acyl-phosphatidylethanolamines and N-acetylethanolamines: proposed role in neurotoxicity Biochem. Pharmacol. 55 1998 719 725
25. W.S. Ho, D.A. Barrett, and M.D. Randall 'Entourage' effects of N-palmitoylethanolamide and N-oleoylethanolamide on vasorelaxation to anandamide occur through TRPV1 receptors Br. J. Pharmacol. 155 2008 837 846
26. J.R. Huguenard Neuronal circuitry of thalamocortical epilepsy and mechanisms of antiabsence drug action Adv. Neurol. 79 1999 991 999
27. S.I. Jaggar, F.S. Hasnie, S. Sellaturay, and A.C. Rice The anti-hyperalgesic actions of the cannabinoid anandamide and the putative CB2 receptor agonist palmitoylethanolamide in visceral and somatic inflammatory pain Pain 76 1998 189 199
28. T. Kainu, A.C. Wikström, J.A. Gustafsson, and M. Pelto-Huikko Localization of the peroxisome proliferator-activated receptor in the brain Neuroreport 5 1994 2481 2485
29. M. Koch, S. Kreutz, C. Böttger, A. Benz, E. Maronde, C. Ghadban, H.W. Korf, and F. Dehghani Palmitoylethanolamide protects dentate gyrus granule cells via peroxisome proliferator-activated receptor-α Neurotox. Res. 19 2011 330 340
30. K.R. Kozak, R.A. Gupta, J.S. Moody, C. Ji, W.E. Boeglin, R.N. DuBois, A.R. Brash, and L.J. Marnett 15-Lipoxygenase metabolism of 2- arachidonylglycerol. Generation of a peroxisome proliferator-activated receptor alpha agonist J. Biol. Chem. 277 2002 23278 23286
31. D.M. Lambert, and V. Di Marzo The palmitoylethanolamide and oleamide enigmas: are these two fatty acid amides cannabimimetic? Curr. Med. Chem. 6 1999 757 773
32. D.M. Lambert, F. Di Paolo, P. Sonveaux, M. Kanyonyo, S.J. Govaerts, E. Hermans, J. Bueb, N.M. Delzenne, and E.J. Tschirhart Analogues and homologues of N-palmitoylethanolamide: a putative endogenous CB2 cannabinoid, as potential ligands for the cannabinoid receptors Biochim. Biophys. Acta 1440 1999 266 274
33. D.M. Lambert, S. Vandervoorde, G. Diependaele, S.J. Govaerts, and A.R. Robert Anticonvulsant activity of N-palmitoylethanolamide, a putative endocannabinoid, in mice Epilepsia 42 2001 321 327
34. D.M. Lambert, S. Vandevoorde, K.O. Jonsson, and C.J. Fowler The palmitoylethanolamide family: a new class of anti-inflammatory agents? Curr. Med. Chem. 9 2002 663 674
35. U.S. Lee, and J. Cui BK channel activation: structural and functional insights Trends Neurosci. 33 2010 415 423
36. J. Lo Verme, G. La Rana, R. Russo, A. Calignano, and D. Piomelli The search for the palmitoylethanolamide receptor Life Sci. 77 2005 1685 1698
37. J. Lo Verme, G. Fu, G. Astarita, G. La Rana, R. Russo, A. Calignano, and D. Piomelli The nuclear receptor peroxisome proliferator-activated receptor-alpha mediates the anti-inflammatory actions of Palmitoylethanolamide Mol. Pharmacol. 67 2005 15 19
38. J. LoVerme, R. Russo, G. La Rana, J. Fu, J. Farthing, and G. Mattace-Raso Rapid broad-spectrum analgesia through activation of peroxisome proliferator-activated receptor-alpha J. Pharmacol. Exp. Ther. 319 2006 1051 1061
39. G. Marsicano, S. Goodenough, K. Monory, H. Hermann, M. Eder, A. Cannich, S.C. Azad, M.G. Cascio, S.O. Gutiérrez, M. van der Stelt, M.L. López-Rodriguez, E. Casanova, G. Schütz, W. Zieglgänsberger, V. Di Marzo, C. Behl, and B. Lutz CB1 cannabinoid receptors and on-demand defense against excitotoxicity Science 302 2003 84 88
40. I. Matias, M.P. Gonthier, P. Orlando, V. Martiadis, L. De Petrocellis, C. Cervino, S. Petrosino, L. Hoareau, F. Festy, R. Pasquali, R. Roche, M. Maj, U. Pagotto, P. Monteleone, and V. Di Marzo Regulation, function, and dysregulation of endocannabinoids in models of adipose and beta-pancreatic cells and in obesity and hyperglycemia J. Clin. Endocrinol. Metab. 91 2006 3171 3180
41. S. Moreno, S. Farioli-Vecchioli, and M.P. Cerù Immunolocalization of peroxisome proliferator-activated receptors and retinoid X receptors in the adult rat CNS Neuroscience 123 2004 131 145
42. G.G. Muccioli, and N. Stella Microglia produce and hydrolyze palmitoylethanolamide Neuropharmacology 54 2008 16 22
43. M. Naccarato, D. Pizzuti, S. Petrosino, M. Simonetto, L. Ferigo, F.C. Grandi, G. Pizzolato, and V. Di Marzo Possible Anandamide and Palmitoylethanolamide involvement in human stroke Lipids Health Dis. 9 2010 47
44. S.E. O'Sullivan Cannabinoids go nuclear: evidence for activation of peroxisome proliferator-activated receptors Br. J. Pharmacol. 152 2007 576 582
45. S.E. O'Sullivan, and D.A. Kendall Cannabinoid activation of peroxisome proliferator-activated receptors: potential for modulation of inflammatory disease Immunobiology 215 2010 611 616
46. F.Y. Onat, R.G. Aker, A.A. Gurbanova, N. Ateş, and G. van Luijtelaar The effect of generalized absence seizures on the progression of kindling in the rat Epilepsia 5 2007 150 156
47. G. Paxinos, and C. Watson The Rat Brain in Stereotaxic Coordinates fourth ed. 1998 Academic Press San Diego
48. S. Petrosino, T. Iuvone, and V. Di Marzo N-palmitoyl-ethanolamine: biochemistry and new therapeutic opportunities Biochimie 92 2010 724 727
49. G. Re, R. Barbero, A. Miolo, and V. Di Marzo Palmitoylethanolamide, endocannabinoids and related cannabimimetic compounds in protection against tissue inflammation and pain: potential use in companion animals Vet. J. 173 2007 21 30
50. E. Russo, R. Citraro, A. Davoli, L. Gallelli, E. Donato Di Paola, and G. De Sarro Ameliorating effects of aripiprazole on cognitive functions and depressive-like behavior in a genetic rat model of absence epilepsy and mild-depression comorbidity Neuropharmacology 64 2013 371 379
51. E. Russo, R. Citraro, S. De Fazio, R. Marra, R. Gitto, A. Chimirri, G. De Sarro, and E.D. Di Paola Enhancement of anti-absence effects of ethosuximide by low doses of a noncompetitive alpha-amino-3-hydroxy-5-methyl-4- isoxazolepropionic acid (AMPA) receptor antagonist in a genetic animal model of absence epilepsy Epilepsy. Behav. 13 2008 295 299
52. E. Russo, R. Citraro, G. Donato, C. Camastra, R. Iuliano, S. Cuzzocrea, A. Constanti, and G. De Sarro mTOR inhibition modulates epileptogenesis, seizures and depressive behavior in a genetic rat model of absence epilepsy Neuropharmacology 2013 25 36
53. E. Russo, R. Citraro, F. Scicchitano, S. De Fazio, I. Perrota, E.D. Di Paola, A. Constanti, and G. De Sarro Effects of early long-term treatment with antiepileptic drugs on development of seizures and depressive-like behavior in a rat genetic absence epilepsy model Epilepsia 52 2011 1341 1350
54. E. Russo, A. Constanti, G. Ferreri, R. Citraro, and G. De Sarro Nifedipine affects the anticonvulsant activity of topiramate in various animal models of epilepsy Neuropharmacology 46 2004 865 878
55. E. Ryberg, N. Larsson, S. Sjögren, S. Hjorth, N.O. Hermansson, J. Leonova, T. Elebring, K. Nilsson, T. Drmota, and P.J. Greasley The orphan receptor GPR55 is a novel cannabinoid receptor Br. J. Pharmacol. 152 2007 1092 1101
56. M. Schomacher, H.D. Müller, C. Sommer, S. Schwab, and W.R. Schäbitz Endocannabinoids mediate neuroprotection after transient focal cerebral ischemia Brain Res. 1240 2008 213 220
57. A. Schreibman Cohen, M. Daley, P. Siddarth, J. Levitt, I.K. Loesch, L. Altshuler, R. Ly, W.D. Shields, S. Gurbani, and R. Caplan Amygdala volumes in childhood absence epilepsy Epilepsy Behav. 16 2009 436 441
58. A.H. Sheerin, X. Zhang, D.M. Saucier, and M.E. Corcoran Selective antiepileptic effects of N-palmitoylethanolamide, a putative endocannabinoid Epilepsia 45 2004 1184 1188
59. T. Sheskin, L. Hanus, J. Slager, Z. Vogel, and R. Mechoulam Structural requirements for binding of anandamide-type compounds to the brain cannabinoid receptor J. Med. Chem. 40 1997 659 667
60. S.D. Skaper, A. Buriani, R. Dal Toso, L. Petrelli, S. Romanello, L. Facci, and A. Leon The ALIAmide palmitoylethanolamide and cannabinoids, but not anandamide, are protective in a delayed postglutamate paradigm of excitotoxic death in cerebellar granule neurons Proc. Natl. Acad. Sci. U. S. A. 93 1996 3984 3999
61. T. Sugiura, S. Kondo, S. Kishimoto, T. Miyashita, S. Nakane, T. Kodaka, Y. Suhara, H. Takayama, and K. Waku Evidence that 2-arachidonoylglycerol but not N-palmitoylethanolamine or anandamide is the physiological ligand for the cannabinoid CB2 receptor. Comparison of the agonistic activities of various cannabinoid receptor ligands in HL-60 cells J. Biol. Chem. 275 2000 605 612
62. Y. Sun, S.P. Alexander, M.J. Garle, C.L. Gibson, K. Hewitt, S.P. Murphy, D.A. Kendall, and A.J. Bennett Cannabinoid activation of PPAR alpha; a novel neuroprotective mechanism Br. J. Pharmacol. 152 2007 734 743
63. Y. Sun, S.P. Alexander, D.A. Kendall, and A.J. Bennett Cannabinoids and PPARalpha signalling Biochem. Soc. Trans. 34 2006 1095 1097
64. 1 receptor agonist, R(+)WIN55,212-2, with a reduced incidence of spike-wave discharges Epilepsia 51 2010 1511 1521